Skip to content

DMT: all studies

Page 78 of 160: studies 771 to 780 of 1,593, newest first. Back to the DMT overview

Research

Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics

SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice December 1, 2025 Dario Jalilzadeh Masah, Derin Marbin, Tomislav Majić 1 citation

Abstract: Aims: Symptoms of depersonalization (DP) and derealization (DR) are commonly reported during the acute effects of classic psychedelics. In some individuals, these symptoms persist, resulting in depersonalization-derealization disorder (DDD), associated with distress and help-seeking behavior. This case series seeks to underscore some of the diagnostic challenges and treatment...

DOI: 10.1024/0939-5911/a000959 (opens in new tab) Psilocybin Psychodynamics Depersonalization Distress +6

A Mesoscale Framework for Psychedelic Drug Action in the Human Brain

bioRxiv November 26, 2025 Rui Dai, Rodrigo Cofré, Christopher Timmermann et al. preprint

The mechanism of psychedelic drug action is a dynamic area of neuroscience, with two major lines of investigation: (1) laboratory studies at the molecular and cellular level, and (2) human neuroimaging studies of functional brain networks. Despite considerable progress, there remains insufficient understanding of the link between molecular/cellular substrates of psychedelics and the whole-brain...

New treatments for OCD? Evidence for cannabinoids and psychedelics.

Journal of Psychiatric Research November 26, 2025 Michael van Ameringen, Vidhi Patel, Beth Patterson et al.

The etiology of OCD is complex and appears to involve multiple biological pathways. Imbalances in central serotonin, dopamine, and glutamate activities are widely thought to play a causative role. Despite strong evidence supporting first-line OCD pharmacotherapies, approximately 40-60 % of OCD patients remain unresponsive and are considered treatment resistant (TR). Although a range of agents...

Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community.

Harm Reduction Journal November 25, 2025 Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al. 1 citation

BACKGROUND: The use of psychedelics is currently increasing in the United States. Awareness of clinical trials investigating the therapeutic applications of psychedelics may result in a record number of people who use psychedelics for the first-time. This study aimed to develop a harm-reduction resource to facilitate safe and successful psychedelic experiences outside of regulated clinical and...

Complexity as a Potential Neurophysiological Correlate of Awe

bioRxiv (Cold Spring Harbor Laboratory) November 21, 2025 Joseph C. C. Chen, Gabriella Mace, Avery Ostrand et al. preprint

Abstract Awe is a positive emotion often accompanied by sensations of vastness and unity, with known benefits for well-being and social behavior. However, its neural underpinnings remain poorly understood. We recorded electroencephalography (EEG) and autonomic physiology in 23 healthy older participants while they watched a nature-based audiovisual film and subjectively rated awe events. Awe...

DOI: 10.1101/2025.11.20.689403 (opens in new tab) Electroencephalography Neurophysiology Neural activity Spectral analysis +4

Psychedelic Rejuvenation Hypothesis: A Framework for Cellular and Psychological Restoration

November 17, 2025 Tony R. Montgomery, Demond M. Grant

Recent research into classical psychedelics, such as psilocybin, LSD, and DMT, has highlighted their therapeutic potential for mental health disorders. However, emerging evidence suggests their utility may extend beyond treatment into the realm of preventive medicine. This manuscript proposes a novel framework positioning psychedelics as agents of cellular and psychological rejuvenation....

DOI: 10.31124/advance.175630073.36585408/v2 (opens in new tab) Rejuvenation Realm Mental health Psychological intervention +3

A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens

Psychoactives November 14, 2025 William Roseby, Catriona Osborn Moar

Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as powerful tools to advance the understanding of consciousness and its relation to brain activity. Psychedelic research has informed neuroscientific theories that attempt to map neural observations of network connectivity and signal diversity to...

DOI: 10.3390/psychoactives4040041 (opens in new tab) Consciousness Interpretability Qualia Narrative +13

Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.

ACS Medicinal Chemistry Letters November 10, 2025 Anna C. Renner, Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that...

Description of samples for chemical analysis.

Figshare November 10, 2025 Marina D. Luccioni (22593281), Jules T. Wyman (22593284), Edgard O. Espinoza (14827902) et al.

The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the source of 5-MeO-DMT in I. alvarius remains unknown. Some amphibians produce chemical defenses endogenously or through symbiotic interactions, while others acquire them from specialized diets. In this study we analyzed toxin gland secretions and diet...

DOI: 10.1371/journal.pone.0335661.s002 (opens in new tab) Sympatric speciation Toad Habitat Ecology +8

Diet and chemical defenses of the Sonoran Desert toad

PLoS One November 10, 2025 Marina D. Luccioni, Jules T. Wyman, Edgard O. Espinoza et al.

The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the source of 5-MeO-DMT in I. alvarius remains unknown. Some amphibians produce chemical defenses endogenously or through symbiotic interactions, while others acquire them from specialized diets. In this study we analyzed toxin gland secretions and diet...

DOI: 10.1371/journal.pone.0335661 (opens in new tab) Sympatric speciation Toad Habitat Sympatry +7